Pharmadrug, Inc. engages in the research, development, and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and naturally derived approved drugs. The company is headquartered in Toronto, Ontario. The company went IPO on 2018-08-16. The firm is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The company also owns 100% of SecureDose Synthetics Inc. a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.
